ישראל -
עברית -
Ministry of Health
נינלארו 4 מג
takeda israel ltd - ixazomib as citrate - קפסולות - ixazomib as citrate 4 mg - ixazomib
ישראל -
עברית -
Ministry of Health
מווקס תמיסה
vitamed pharmaceutical industries ltd - bromhexine hydrochloride - תמיסה - bromhexine hydrochloride 2.00 mg/ml - bromhexine - bromhexine - bronchial mucolytic. it can also be given by inhalation as an aerosol solution.
ישראל -
עברית -
Ministry of Health
מוקולס תמיסה
vitamed pharmaceutical industries ltd - bromhexine hydrochloride - תמיסה - bromhexine hydrochloride 2 mg/ml - bromhexine
ישראל -
עברית -
Ministry of Health
בימטילול טבע
teva israel ltd - bimatoprost; timolol as maleate - טיפות עיניים - timolol as maleate 5 mg / 1 ml; bimatoprost 0.3 mg / 1 ml - timolol, combinations
ישראל -
עברית -
Ministry of Health
פרבליפ 10
unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin
ישראל -
עברית -
Ministry of Health
פוזיד
teva pharmaceutical industries ltd, israel - furosemide - טבליה - furosemide 40 mg - furosemide - furosemide - edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. adjunctive therapy in acute pulmonary edema. treatment of hypertension.
ישראל -
עברית -
Ministry of Health
פוזיד טבליות
teva pharmaceutical industries ltd, israel - furosemide - טבליה - furosemide 40 mg - furosemide
ישראל -
עברית -
Ministry of Health
סליידר
unipharm ltd, israel - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 20 mg - sildenafil - sildenafil - for adults > 18 years: indicated for treatment of primary pulmonary hypertension (pph) pulmonary hypertension (ph) associated with connective tissue disease (ctd) or ph following surgical repair at least 5 years previously of atrial septal defect (asd) ventricular septal defect (vsd) patent ductus arteriosus (pda) or aorto-pulmonary window.
ישראל -
עברית -
Ministry of Health
אקסטביה
novartis pharma services ag - interferon beta 1b 0.3 mg - powder and solvent for solution for injection - interferon beta-1b - extavia is indicated for the treatment of:• for use in relapsing-remitting and relapsing-progressive multiple sclerosis. it is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite ms, and who have experienced at least two exacerbations over the last two years.extavia reduces the frequency of clinical exacerbations.in secondary progressive multiple sclerosis extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. compared with placebo, patients receiving extavia showed a statistically significant delay in time to progression of multiple sclerosis. the treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). patients receiving extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. see also section 5.1 “pharm